DYRK2 phosphorylates and activates both HSF1 and the 26S proteasome and thereby activates the proteotoxic stress pathway promoting tumorigenesis in cancers such as triple-negative breast cancer (TNBC) and multiple myeloma (MM). Here, DYRK2 is linked to triple-negative breast carcinoma.